First Global Research has published a research report on Pfizer Inc PFE.
In the report, First Global wrote, "Pfizer Inc. (PFE) delivered a respectable performance for Q2 CY11 that met our expectations. The company's non-GAAP EPS of 60 cents for the quarter came in line with our estimate, driven by a decent topline performance, as well as its ongoing cost control and rationalization measures. Management also kept its guidance for both CY11 and CY12 unchanged."
First Global rated Pfizer a Moderate Outperform with no price target given. Pfizer closed Monday at $17.68.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in